La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Debt-to-EBITDA : 0.01 (As of Jun. 2022)

View and export this data going back to 1994. Start your Free Trial

What is La Jolla Pharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

La Jolla Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.16 Mil. La Jolla Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.08 Mil. La Jolla Pharmaceutical Co's annualized EBITDA for the quarter that ended in Jun. 2022 was $21.20 Mil. La Jolla Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was 0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for La Jolla Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

LJPC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.29 Med: -0.11 Max: 0.08
Current: 0.02

During the past 13 years, the highest Debt-to-EBITDA Ratio of La Jolla Pharmaceutical Co was 0.08. The lowest was -0.29. And the median was -0.11.

LJPC's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.37 vs LJPC: 0.02

La Jolla Pharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for La Jolla Pharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

La Jolla Pharmaceutical Co Debt-to-EBITDA Chart

La Jolla Pharmaceutical Co Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Debt-to-EBITDA

Get a 7-Day Free Trial

-0.29

-0.11

0.08

La Jolla Pharmaceutical Co Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Debt-to-EBITDA	Get a 7-Day Free Trial															0.10	0.69	0.10	0.02	0.01

Competitive Comparison of La Jolla Pharmaceutical Co's Debt-to-EBITDA

For the Biotechnology subindustry, La Jolla Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

La Jolla Pharmaceutical Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, La Jolla Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where La Jolla Pharmaceutical Co's Debt-to-EBITDA falls into.

La Jolla Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

La Jolla Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.479	+	0.164)	/	32.048
	=	0.08

La Jolla Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.157	+	0.075)	/	21.204
	=	0.01

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.

La Jolla Pharmaceutical Co (NAS:LJPC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

La Jolla Pharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of La Jolla Pharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » La Jolla Pharmaceutical Co (NAS:LJPC) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Jones Road, Suite 400, Waltham, MA, USA, 02451

Website

http://www.ljpc.com

La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.

Executives

Larry G. Edwards	director, officer: Chief Executive Officer	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David A Ramsay	director	HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Michael S Hearne	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Robert Rosen	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Kevin C Tang	director, 10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Darryl Wellinghoff	officer: Chief Commercial Officer	4550 TOWNE CENTRE COURT SAN DIEGO CA 92121
Lakhmir S Chawla	officer: Chief Medical Officer	1960 KIRBY ROAD, MCLEAN VA 22101
Jennifer Carver	officer: Sr. Vice President, Operations	725 NEWPORT STREET, DENVER CO 80220
James Rolke	officer: Chief Scientific Officer	10182 TELESIS COURT, 6TH FLOOR, SAN DIEGO CA 92121
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc	10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
George F Tidmarsh	director, officer: President, CEO & Secretary